Abionyx Pharma Liabilities 2024

Abionyx Pharma Aktienanalyse

What does Abionyx Pharma do?

Abionyx Pharma SA is a biotechnology company based in France that specializes in the development and commercialization of innovative therapeutic approaches for rare diseases. The company was founded in 2000 by a group of scientists and pharmaceutical experts and has since become a leading company in the industry. The business model of Abionyx Pharma is based on the discovery and development of drugs for rare diseases. The company focuses in particular on diseases for which there are still no or only inadequate therapies. With this focus, Abionyx Pharma takes advantage of orphan drug designations and other incentive programs offered by governments and authorities around the world. These programs are intended to provide incentives for the research and development of drugs for rare diseases. Abionyx Pharma has a wide range of products in various stages of development. These include therapeutics for musculoskeletal diseases, neural disorders, and chronic inflammation. The company also has a portfolio of compounds and drugs that can be used as a platform for the development of drugs for other diseases. One of Abionyx Pharma's key products is ONO-8455, a treatment package for osteoarthritis. This is a common joint disease caused by progressive cartilage wear. ONO-8455 has the potential to be a very important therapy option for the disease and could potentially become a blockbuster drug. Another important product from Abionyx Pharma is ABX464. This is a topical therapy for the treatment of hemorrhoid inflammation. ABX464 has been tested in clinical trials and has shown promising results in terms of its effectiveness in treating hemorrhoids. Abionyx Pharma also has other projects in the pipeline, including a therapy for Fabry disease. Fabry disease is a very rare genetic disorder that affects the metabolism of lipids and other important molecules in the body. Abionyx Pharma is developing a therapy based on a novel technology that acts through DNA methylation. To achieve its business goals, Abionyx Pharma works closely with scientific and clinical partners. It also forms strategic alliances with other pharmaceutical companies to market its products globally and gain a significant market share. Overall, Abionyx Pharma is an attractive company for investors looking for a biotechnology company specializing in the development and commercialization of drugs for rare diseases. The company has a strong portfolio of products in various stages of development and has already presented promising results. With its close collaboration with partners and strategic alliances, it is able to market its products globally and remain a strong competitor in the industry. Abionyx Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Abionyx Pharma's Liabilities

Abionyx Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Abionyx Pharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Abionyx Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Abionyx Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Abionyx Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Abionyx Pharma Stock

What is the level of liabilities of Abionyx Pharma this year?

Abionyx Pharma has a debt balance of 6.91 M EUR this year.

What were the liabilities of Abionyx Pharma compared to the previous year?

The liabilities of Abionyx Pharma have increased by -20.13% dropped compared to the previous year.

What are the consequences of high debt for investors of Abionyx Pharma?

High liabilities can pose a risk for investors of Abionyx Pharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Abionyx Pharma?

Low liabilities mean that Abionyx Pharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Abionyx Pharma affect the company?

An increase in liabilities of Abionyx Pharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Abionyx Pharma affect the company?

A decrease in the liabilities of Abionyx Pharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Abionyx Pharma?

Some factors that can influence the liabilities of Abionyx Pharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Abionyx Pharma so important for investors?

The liabilities of Abionyx Pharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Abionyx Pharma take to modify the liabilities?

To change its liabilities, Abionyx Pharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Abionyx Pharma pay?

Over the past 12 months, Abionyx Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abionyx Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Abionyx Pharma?

The current dividend yield of Abionyx Pharma is .

When does Abionyx Pharma pay dividends?

Abionyx Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abionyx Pharma?

Abionyx Pharma paid dividends every year for the past 0 years.

What is the dividend of Abionyx Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abionyx Pharma located?

Abionyx Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abionyx Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abionyx Pharma from 6/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/13/2024.

When did Abionyx Pharma pay the last dividend?

The last dividend was paid out on 6/13/2024.

What was the dividend of Abionyx Pharma in the year 2023?

In the year 2023, Abionyx Pharma distributed 0 EUR as dividends.

In which currency does Abionyx Pharma pay out the dividend?

The dividends of Abionyx Pharma are distributed in EUR.